Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2016; 05(03): 112-120
DOI: 10.4103/2278-330X.187575
Review Article

Gynecological cancers: A summary of published Indian data

Amita Maheshwari
Department of Gynecologic Oncology, Tata Memorial Centre, Mumbai, Maharashtra
,
Neha Kumar
Department of Gynecologic Oncology, Tata Memorial Centre, Mumbai, Maharashtra
,
Umesh Mahantshetty
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, Maharashtra
› Author Affiliations
Financial support and sponsorship: Nil.
› Further Information
Also available at
 PDF Download Permissions and Reprints

Abstract

Gynecological cancers are among the most common cancers in women and hence an important public health issue. Due to the lack of cancer awareness, variable pathology, and dearth of proper screening facilities in developing countries such as India, most women report at advanced stages, adversely affecting the prognosis and clinical outcomes. Ovarian cancer has emerged as one of the most common malignancies affecting women in India and has shown an increase in the incidence rates over the years. Although cervical cancer is on a declining trend, it remains the second most common cancer in women after breast cancer. Many researchers in India have published important data in the field of gynecologic oncology, covering all domains such as basic sciences, preventive oncology, pathology, radiological imaging, and clinical outcomes. This work has given us an insight into the in-depth understanding of these cancers as well as the demographics and survival rates in the Indian population. This aim of this review is to discuss the important studies done in India for all gynecological cancers.

Key words

Cancer - gynecological - India - Indian


Publication History

Article published online:
28 December 2020

© 2016. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 ICO Information Centre on HPV and Cancer (Summary Report 2014-08-22). Human Papillomavirus and Related Diseases in India; 2014.
  • 2 Basu M, Bhattacharya R, Ray U, Mukhopadhyay S, Chatterjee U, Roy SS. Invasion of ovarian cancer cells is induced by PITX2-mediated activation of TGF-ß and Activin-A. Mol Cancer 2015;14:162.
  • 3 Choudhuri S, Sharma C, Banerjee A, Kumar S, Kumar L, Singh N. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. Mol Cell Biochem 2014;386:259-69.
  • 4 Patel S, Kumar L, Singh N. Metformin and epithelial ovarian cancer therapeutics. Cell Oncol (Dordr) 2015;38:365-75.
  • 5 Singh RK, Gaikwad SM, Jinager A, Chaudhury S, Maheshwari A, Ray P. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Lett 2014;354:254-62.
  • 6 Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int 2014;2014:401245.
  • 7 Ravikumar G, Crasta JA. Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer 2013;2:87-90.
  • 8 Shilpa V, Bhagat R, Premalata CS, Pallavi VR, Ramesh G, Krishnamoorthy L. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma - An Indian study. Tumour Biol 2014;35:4277-84.
  • 9 Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S, Banerjee BD. Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: A pilot study. Int J Biochem Mol Biol 2014;5:1-10.
  • 10 Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: A 10-year study in a tertiary hospital of Eastern India. J Cancer Res Ther 2011;7:433-7.
  • 11 Deodhar KK, Suryawanshi P, Shah M, Rekhi B, Chinoy RF. Immature teratoma of the ovary: A clinicopathological study of 28 cases. Indian J Pathol Microbiol 2011;54:730-5.
  • 12 Menon S, Deodhar K, Rekhi B, Dhake R, Gupta S, Ghosh J, et al. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases. Indian J Pathol Microbiol 2013;56:365-71.
  • 13 Kane SV, Bharadwaj R, Tongaonkar HB. Borderline epithelial tumours of the ovary - A retrospective analysis of 31 cases. Indian J Cancer 1999;36:18-31.
  • 14 Ranganath R, Sridevi V, Shirley SS, Shantha V. Clinical and pathologic prognostic factors in adult granulosa cell tumors of the ovary. Int J Gynecol Cancer 2008;18:929-33.
  • 15 Gupta N, Rajwanshi A, Dhaliwal LK, Khandelwal N, Dey P, Srinivasan R, et al. Fine needle aspiration cytology in ovarian lesions: An institutional experience of 584 cases. Cytopathology 2012;23:300-7.
  • 16 Maheshwari A, Gupta S, Kane S, Kulkarni Y, Goyal BK, Tongaonkar HB. Accuracy of intraoperative frozen section in the diagnosis of ovarian neoplasms: Experience at a tertiary oncology center. World J Surg Oncol 2006;4:12.
  • 17 Rekhi B, George S, Madur B, Chinoy RF, Dikshit R, Maheshwari A. Clinicopathological features and the value of differential cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa. Diagn Pathol 2008;3:39.
  • 18 Ghosh J, Thulkar S, Kumar R, Malhotra A, Kumar A, Kumar L. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: A pilot study. Natl Med J India 2013;26:327-31.
  • 19 Chandrashekhara SH, Thulkar S, Srivastava DN, Kumar L, Hariprasad R, Kumar S, et al. Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer. Br J Radiol 2011;84:38-43.
  • 20 Rajanbabu A, Kuriakose S, Ahmad SZ, Khadakban T, Khadakban D, Venkatesan R, et al. Evolution of surgery in advanced epithelial ovarian cancer in a dedicated gynaecologic oncology unit-seven year audit from a tertiary care centre in a developing country. Ecancermedicalscience 2014;8:422.
  • 21 Deo SV, Goyal H, Shukla NK, Raina V, Kumar L, Srinivas G. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006;43:117-21.
  • 22 Talukdar S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol 2014;132:28-32.
  • 23 Maheshwari A, Gupta S, Prabhash K, Tongaonkar HB. Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer. Indian J Cancer 2010;47:225-6.
  • 24 Jaka RC, Somashekhar SP, Zaveri SS, Ahmed Z, Ashwin KR. Intraperitoneal chemotherapy for epithelial ovarian cancer - Single center experience. Indian J Surg Oncol 2012;3:262-6.
  • 25 Chitrathara K, Sheikh ZA, Vijaykumar DK, Kuriakose S, Anupama R, Nandeesh M. Is hysterectomy needed in ovarian cancer? Indian J Cancer 2011;48:471-6.
  • 26 Rema PN, Suchetha S, Mathew AP, Mathew A, Sebastian P. Secondary cytoreduction in epithelial ovarian cancer recurrence: A perspective from a regional cancer center in India. J Reprod Med 2009;54:506-10.
  • 27 Gupta S, Goyal G, Ghosh J, Bhosale BB,Bajpai J, Maheshwari A. A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer. J Clin Oncol 2013 ASCO Annual Meeting Abstracts 2013;31:5554.
  • 28 Shetty UM, Shankar S, Engineer R, Chopra S, Gupta S, Maheshwari A, et al. Image-guided intensity-modulated whole abdominal radiation therapy in relapsed epithelial ovarian cancers: A feasibility study. J Cancer Res Ther 2013;9:17-21.
  • 29 Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005;116:617-23.
  • 30 Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008;123:153-60.
  • 31 Pimple S, Shastri SS. Comparative evaluation of human papilloma virus-DNA test verses colposcopy as secondary cervical cancer screening test to triage screen positive women on primary screening by visual inspection with 5% acetic acid. Indian J Cancer 2014;51:117-23.
  • 32 Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
  • 33 Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA screening by primary health workers: Randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014;106:dju009.
  • 34 Deodhar K, Gheit T, Vaccarella S, Romao CC, Tenet V, Nene BM, et al. Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol 2012;84:1054-60.
  • 35 Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009;33:446-50.
  • 36 Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010;36:123-32.
  • 37 Shaikh R, Dora TK, Chopra S, Maheshwari A, Kedar K D, Bharat R, et al. In vivo Raman spectroscopy of human uterine cervix: Exploring the utility of vagina as an internal control. J Biomed Opt 2014;19:087001.
  • 38 Halder K, Chachra KL, Sodhani P, Gupta S. Utility of imprint cytology for early presumptive diagnosis in clinically suspicious cervical cancer. Acta Cytol 2008;52:286-93.
  • 39 Maharjan S, Sharma P, Patel CD, Sharma DN, Dhull VS, Jain SK, et al. Prospective evaluation of qualitative and quantitative 18F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix. Nucl Med Commun 2013;34:741-8.
  • 40 Chopra S, Verma A, Kundu S, Engineer R, Medhi S, Mahantshetty U, et al. Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. J Cancer Res Ther 2012;8:68-73.
  • 41 Sankaranarayanan R, Keshkar V, Kothari A, Kane S, Fayette JM, Shastri S. Effectiveness and safety of loop electrosurgical excision procedure for cervical neoplasia in rural India. Int J Gynaecol Obstet 2009;104:95-9.
  • 42 Shrivastava S, Mahantshetty U, Engineer R, Tongaonkar H, Kulkarni J, Dinshaw K. Treatment and outcome in cancer cervix patients treated between 1979 and 1994: A single institutional experience. J Cancer Res Ther 2013;9:672-9.
  • 43 Kundargi RS, Guruprasad B, Rathod PS, Shakuntala P, Shobha K, Pallavi V, et al. Risk strata-based therapy and outcome in stage Ib-IIa carcinoma cervix: Single-centre ten-year experience. Ecancermedicalscience 2013;7:341.
  • 44 Pallavi VR, Devi KU, Mukherjee G, Ramesh C, Bafna UD. Relationship between lymph node metastases and histopathological parameters in carcinoma cervix: A multivariate analysis. J Obstet Gynaecol 2012;32:78-80.
  • 45 Gupta S, Sodhani P, Singh V, Sehgal A. Role of vault cytology in follow-up of hysterectomized women: Results and inferences from a low resource setting. Diagn Cytopathol 2013;41:762-6.
  • 46 Mahantshetty U, Shrivastava S, Kalyani N, Banerjee S, Engineer R, Chopra S. Template-based high-dose-rate interstitial brachytherapy in gynecologic cancers: A single institutional experience. Brachytherapy 2014;13:337-42.
  • 47 Mahantshetty U, Kalyani N, Engineer R, Chopra S, Jamema S, Ghadi Y, et al. Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix. Brachytherapy 2014;13:548-53.
  • 48 Mishra SK, Laskar S, Muckaden MA, Mohindra P, Shrivastava SK, Dinshaw KA. Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. J Cancer Res Ther 2005;1:208-12.
  • 49 Singh RK, Maulik S, Mitra S, Mondal RK, Basu PS, Roychowdhury S, et al. Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients: Correlation with recurrence of the disease. Int J Gynecol Cancer 2006;16:1048-54.
  • 50 Rekhi B, Patil B, Deodhar KK, Maheshwari A, Kerkar RA, Gupta S, et al. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India. Ann Diagn Pathol 2013;17:1-9.
  • 51 Mahantshetty U, Aggarwal A, Ganesh B, Saoba S, Mulla S, Engineer R, et al. Clinical outcome of early-stage endometroid adenocarcinoma: A tertiary cancer center experience. Int J Gynecol Cancer 2013;23:1446-52.
  • 52 Rathod PS, Shakuntala PN, Pallavi VR, Kundaragi R, Shankaranand B, Vijay CR, et al. The risk and pattern of pelvic and para aortic lymph nodal metastasis in patients with intermediate and high risk endometrial cancer. Indian J Surg Oncol 2014;5:109-14.
  • 53 Gholkar NS, Saha SC, Prasad G, Bhattacharya A, Srinivasan R, Suri V. The accuracy of integrated [(18) F] fluorodeoxyglucose-positron emission tomography/computed tomography in detection of pelvic and para-aortic nodal metastasis in patients with high risk endometrial cancer. World J Nucl Med 2014;13:170-7.
  • 54 Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, et al. Carcinoma endometrium: Role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 2012;37:649-55.
  • 55 Somashekhar SP, Jaka RC, Zaveri SS. Prospective randomized study comparing robotic-assisted hysterectomy and regional lymphadenectomy with traditional laparotomy for staging of endometrial carcinoma initial Indian experience. Indian J Surg Oncol 2014;5:217-23.
  • 56 Biswas A, Patel F, Kumar P, Srinivasan R, Bera A, Sharma SC, et al. Uterine sarcoma-current management and experience from a regional cancer centre in North India. Arch Gynecol Obstet 2013;288:873-82.
  • 57 Anupama R, Kuriakose S, Vijaykumar DK, Pavithran K, Jojo A, Indu RN, et al. Carcinosarcoma of the uterus-a single institution retrospective analysis of the management and outcome and a brief review of literature. Indian J Surg Oncol 2013;4:222-8.
  • 58 Deodhar KK, Goyal P, Rekhi B, Menon S, Maheshwari A, Kerkar R, et al. Uterine smooth muscle tumors of uncertain malignant potential and atypical leiomyoma: A morphological study of these grey zones with clinical correlation. Indian J Pathol Microbiol 2011;54:706-11.
  • 59 Chhabra S, Bhavani M, Deshpande A. Trends of vulvar cancer. J Obstet Gynaecol 2014;34:165-8.
  • 60 Sharma DN, Rath GK, Kumar S, Bhatla N, Julka PK, Sahai P. Treatment outcome of patients with carcinoma of vulva: Experience from a tertiary cancer center of India. J Cancer Res Ther 2010;6:503-7.
  • 61 Pingley S, Shrivastava SK, Sarin R, Agarwal JP, Laskar S, Deshpande DD, et al. Primary carcinoma of the vagina: Tata Memorial Hospital experience. Int J Radiat Oncol Biol Phys 2000;46:101-8.
  • 62 Gulia S, Bajpai J, Gupta S, Maheshwari A, Deodhar K, Kerkar RA, et al. Outcome of gestational trophoblastic neoplasia: Experience from a tertiary cancer centre in India. Clin Oncol (R Coll Radiol) 2014;26:39-44.
  • 63 Chauhan A, Dave K, Desai A, Mankad M, Patel S, Dave P. High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: Thirteen years of experience. J Reprod Med 2010;55:333-40.
  • 64 Rathod PS, Kundargi R, Pallavi VR, Vijay CR, Devi UK, Bafna UD. Refractory gestational trophoblastic neoplasia: A novel drug combination with paclitaxel and carboplatin produces durable complete remission. Int J Gynecol Cancer 2015;25:1737-41.